- Home Page
- Company Profile
-
Our Products
- Anti Cancer Capsule
-
Anti Cancer Injection
- 300 mcg Filgrastim Injection
- Nimotuzumab Injection
- 2 Mg Bortezomib Injection
- 440 mg Trastuzumab Injection
- 40 mcg Darbepoetin Alfa Injection
- 1000 mg Gemcitabine Injection
- 38 mg Gemcitabine Injection
- 300 mcg Filgrastim Injection
- 260 mg Paclitaxel Injection
- 450 mg Carboplatin Injection
- 3.75 mg Leuprolide Acetate Injection
- 6 mg Pegfilgrastim Injection
- Pegfilgrastim Injection
- Anti Cancer Tablet
- Anti Cancer Medicine
- Nefroglogy Medicine
- HIV Medicine
- Contact Us
X
440 mg Trastuzumab Injection
Product Details:
- Drug Type General Medicines
- Function Anti-Cancer
- Dosage As per doctor Recommendation
- Suitable For Suitable For All
- Storage Instructions Dry place
- Click to view more
X
Price And Quantity
- 50 Box
Product Specifications
- As per doctor Recommendation
- Dry place
- Anti-Cancer
- Suitable For All
- General Medicines
Trade Information
- Cash in Advance (CID)
- AS per Requirement Per Month
- As per Location Days
- Yes
- Contact us for information regarding our sample policy
- All India
Product Description
440 mg Trastuzumab Injection that proposed by us is sourced from some of authorized pharmaceutical dealers after testing its effectiveness and purity. This type of injection is utilized in the treatment of stomach cancer as well as breast cancer. Such a medication is formulated and composed under the expert pharmaceutical professionals by following set quality standards, and using laboratory tested chemical substances that guarantee its high effect and negligible side-effects. The 440 mg Trastuzumab Injection is unadulterated, and comes in secured packaging.
Other Products in 'Anti Cancer Injection' category
Contact Details
GALAXY LIFE CARE
Plot No 8, Office No 301, 3rd Floor, Chopra Commercial Complex, Delhi - 110092, India
Mr Gopal Jha
(Proprietor)
|
|
|
 |
|
Getdistributors.comSME TimesBlog
India's Largest B2B Marketplace, Connecting Buyers and Sellers.
Privacy Policy- Terms of Use © 1999-2017 Infocom Network Limited. All rights reserved.